Information Provided By:
Fly News Breaks for August 8, 2018
REGN
Aug 8, 2018 | 12:30 EDT
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
News For REGN From the Last 2 Days
There are no results for your query REGN